Dutasteride and prostate cancer.

نویسندگان

  • Lambertus A Kiemeney
  • Maarten C Bosland
چکیده

Please be advised that this information was generated on 2017-04-08 and may be subject to change.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

PURPOSE We assessed whether dutasteride enhances the usefulness of total prostate specific antigen for diagnosing clinically significant prostate cancer. MATERIALS AND METHODS The 4-year REDUCE study evaluated the efficacy and safety of 0.5 mg dutasteride daily for prostate cancer risk reduction in men with a prostate specific antigen of 2.5 to 10.0 ng/ml and a negative prostate biopsy. Speci...

متن کامل

Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.

BACKGROUND In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, dutasteride reduced the relative risk of prostate cancer (CaP) diagnosis over a 4-year period by 22.8%, but questions remain regarding the cost-effectiveness of widespread utilization. We evaluated the cost utility of chemoprevention using dutasteride in men at elevated risk for CaP. METHODS A Markov decision...

متن کامل

Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice

BACKGROUND The prostate cancer prevention trial (PCPT) and Reduction by dutasteride of Prostate Cancer Events (REDUCE) trial found that 5α-reductase (5αR) inhibitors finasteride and dutasteride respectively, decreased prostate cancer prevalence but also increased the incidence of high-grade tumors. 5αR2 is the main isoenzyme in normal prostate tissue; however, most prostate tumors have high 5αR...

متن کامل

Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.

BACKGROUND Androgens play a crucial role in prostate cancer, hence the androgenic pathway has become an important target of therapeutic intervention. Previously we discovered that gene fusions between the 5'-untranslated region of androgen regulated gene TMPRSS2 and the ETS transcription factor family members were present in a majority of the prostate cancer cases. The resulting aberrant overex...

متن کامل

Asian Perspective on Prostate Cancer Prevention

In the April, 2009, initial results of REDUCE study (REduction by DUtasteride of prostate Cancer Events study) were reported. A five α-reductase inhibitor, dutasteride, which inhibits testosterone conversion to dihydrotestosterone (DHT, a potent androgen on prostate cancer carcinogenesis and progression), reduced the prostate cancer detection significantly in the prostate cancerhigh risk group ...

متن کامل

Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.

PURPOSE Prostatic dihydrotestosterone (DHT) concentration is regulated by precursors from systemic circulation and prostatic enzymes of androgen metabolism, particularly 5alpha-reductases (i.e., SRD5A1 and SRD5A2). Therefore, the levels of expression SRD5A1 and SRD5A2 and the antiprostatic cancer growth response to finasteride, a selective SRD5A2 inhibitor, versus the dual SRD5A1 and SRD5A2 inh...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The New England journal of medicine

دوره 363 8  شماره 

صفحات  -

تاریخ انتشار 2010